BRPI0921593B8 - processo para preparar compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina e compostos relacionados - Google Patents
processo para preparar compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina e compostos relacionadosInfo
- Publication number
- BRPI0921593B8 BRPI0921593B8 BRPI0921593A BRPI0921593A BRPI0921593B8 BR PI0921593 B8 BRPI0921593 B8 BR PI0921593B8 BR PI0921593 A BRPI0921593 A BR PI0921593A BR PI0921593 A BRPI0921593 A BR PI0921593A BR PI0921593 B8 BRPI0921593 B8 BR PI0921593B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- preparing
- fluorophenoxymethyl
- phenyl
- piperidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11454108P | 2008-11-14 | 2008-11-14 | |
US61/114,541 | 2008-11-14 | ||
PCT/US2009/064304 WO2010056938A1 (en) | 2008-11-14 | 2009-11-13 | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0921593A2 BRPI0921593A2 (pt) | 2015-08-18 |
BRPI0921593B1 BRPI0921593B1 (pt) | 2021-05-04 |
BRPI0921593B8 true BRPI0921593B8 (pt) | 2021-05-25 |
Family
ID=41666409
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921595A BRPI0921595B8 (pt) | 2008-11-14 | 2009-11-13 | sal monocloridrato cristalino de 4-[2,4,6-(trifluorfenoximetil)fenil]piperidina, seu processo de preparo e usos |
BRPI0921596-4A BRPI0921596B1 (pt) | 2008-11-14 | 2009-11-13 | Compostos de 4-[2-(2-fluorfenoximetil)fenil]piperidina, composição, método de preparação e uso relacionados |
BRPI0921593A BRPI0921593B8 (pt) | 2008-11-14 | 2009-11-13 | processo para preparar compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina e compostos relacionados |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921595A BRPI0921595B8 (pt) | 2008-11-14 | 2009-11-13 | sal monocloridrato cristalino de 4-[2,4,6-(trifluorfenoximetil)fenil]piperidina, seu processo de preparo e usos |
BRPI0921596-4A BRPI0921596B1 (pt) | 2008-11-14 | 2009-11-13 | Compostos de 4-[2-(2-fluorfenoximetil)fenil]piperidina, composição, método de preparação e uso relacionados |
Country Status (29)
Country | Link |
---|---|
US (22) | US8304433B2 (pt) |
EP (3) | EP2358675B9 (pt) |
JP (6) | JP5529150B2 (pt) |
KR (3) | KR101685186B1 (pt) |
CN (3) | CN102209712B (pt) |
AR (3) | AR074128A1 (pt) |
AU (3) | AU2009313948B2 (pt) |
BR (3) | BRPI0921595B8 (pt) |
CA (3) | CA2739992C (pt) |
CL (2) | CL2011001088A1 (pt) |
CO (2) | CO6361988A2 (pt) |
CY (3) | CY1113622T1 (pt) |
DK (3) | DK2358675T3 (pt) |
ES (3) | ES2397247T3 (pt) |
HK (3) | HK1160449A1 (pt) |
HR (3) | HRP20120897T1 (pt) |
IL (2) | IL212230A (pt) |
MX (3) | MX2011005088A (pt) |
MY (2) | MY151229A (pt) |
NZ (2) | NZ592413A (pt) |
PL (3) | PL2358676T3 (pt) |
PT (3) | PT2358675E (pt) |
RU (2) | RU2503662C2 (pt) |
SG (1) | SG171311A1 (pt) |
SI (3) | SI2358675T1 (pt) |
SM (3) | SMT201200063B (pt) |
TW (3) | TWI443087B (pt) |
WO (3) | WO2010056938A1 (pt) |
ZA (1) | ZA201103495B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2358675T3 (da) | 2008-11-14 | 2013-01-14 | Theravance Inc | 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser |
EP2523945A1 (en) | 2010-01-11 | 2012-11-21 | Theravance, Inc. | 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors |
WO2011119461A1 (en) * | 2010-03-22 | 2011-09-29 | Theravance, Inc. | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
EP2560646B1 (en) * | 2010-04-22 | 2014-12-17 | Theravance Biopharma R&D IP, LLC | Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain |
CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
US9544692B2 (en) * | 2012-11-19 | 2017-01-10 | Bitwave Pte Ltd. | System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability |
CN115813923A (zh) * | 2016-08-30 | 2023-03-21 | 施万生物制药研发Ip有限责任公司 | 用于治疗神经性起立性低血压的化合物 |
WO2019232010A1 (en) | 2018-06-01 | 2019-12-05 | Theravance Biopharma R&D Ip, Llc | PROCESS FOR PREPARING 2-(1-(tert-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID |
TW202345817A (zh) | 2022-03-28 | 2023-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 治療患有多系統萎縮之個體的方法 |
CN114957098B (zh) * | 2022-06-02 | 2024-03-29 | 和鼎(南京)医药技术有限公司 | 一种制备喷他佐辛中间体的方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
DE2549999A1 (de) | 1975-11-07 | 1977-05-12 | Boehringer Mannheim Gmbh | Piperidin-derivate und verfahren zu ihrer herstellung |
US4241071A (en) | 1977-01-27 | 1980-12-23 | American Hoechst Corporation | Antidepressant (α-phenyl-2-tolyl)azacycloalkanes |
IL56369A (en) | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
EP0190496A3 (en) | 1984-12-13 | 1987-05-27 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
DE3835291A1 (de) | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
GB9324018D0 (en) | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
EP1097137A1 (en) * | 1998-07-10 | 2001-05-09 | AstraZeneca AB | N-substituted naphthalene carboxamides as neurokinin-receptor antagonists |
GB9922521D0 (en) | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
US6518284B2 (en) | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
ES2157148B1 (es) * | 1998-11-18 | 2002-03-01 | Faes Fabrica Espanola De Produ | Nuevas piperidinas 4-sustituidas. |
AU763356C (en) * | 1999-12-27 | 2004-08-26 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
US6630504B2 (en) | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
US7384941B2 (en) | 2002-08-23 | 2008-06-10 | Eli Lilly And Company | 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
CN1767829A (zh) * | 2003-04-04 | 2006-05-03 | H.隆德贝克有限公司 | 作为5-羟色胺再摄取抑制剂的4-(2-苯氧基苯基)-哌啶或-1,2,3,6-四氢吡啶衍生物 |
PT1635828E (pt) * | 2003-04-04 | 2008-07-01 | Lundbeck & Co As H | Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina |
WO2004110995A1 (en) | 2003-06-17 | 2004-12-23 | Pfizer Limited | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
TW200900399A (en) | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
WO2005068447A1 (en) | 2004-01-13 | 2005-07-28 | Pfizer Limited | Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-upatke inhibitors |
WO2005092835A1 (en) | 2004-03-05 | 2005-10-06 | Eli Lilly And Company | Pharmaceutical compounds |
WO2005105763A1 (en) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
GB0505437D0 (en) | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
US20070142389A1 (en) * | 2005-12-20 | 2007-06-21 | Pfizer Inc. | Piperidine derivatives |
US20070249607A1 (en) * | 2006-04-17 | 2007-10-25 | Bristol-Myers Squibb Company | Nk-1 and serotonin transporter inhibitors |
WO2008023258A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
CA2664245A1 (en) * | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor modulators |
US8026257B2 (en) | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
KR20110026481A (ko) | 2008-06-20 | 2011-03-15 | 메타볼렉스, 인코포레이티드 | 아릴 gpr119 작동약 및 이의 용도 |
TWI438190B (zh) | 2008-07-24 | 2014-05-21 | Theravance Inc | 3-(苯氧基苯基甲基)吡咯啶化合物 |
DK2358675T3 (da) | 2008-11-14 | 2013-01-14 | Theravance Inc | 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser |
EP2523945A1 (en) | 2010-01-11 | 2012-11-21 | Theravance, Inc. | 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors |
WO2011119461A1 (en) | 2010-03-22 | 2011-09-29 | Theravance, Inc. | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
CN115813923A (zh) * | 2016-08-30 | 2023-03-21 | 施万生物制药研发Ip有限责任公司 | 用于治疗神经性起立性低血压的化合物 |
-
2009
- 2009-11-13 DK DK09752688.3T patent/DK2358675T3/da active
- 2009-11-13 KR KR1020117013185A patent/KR101685186B1/ko active IP Right Grant
- 2009-11-13 ES ES09752988T patent/ES2397247T3/es active Active
- 2009-11-13 MY MYPI20111690 patent/MY151229A/en unknown
- 2009-11-13 KR KR1020117013510A patent/KR101656339B1/ko active IP Right Grant
- 2009-11-13 AU AU2009313948A patent/AU2009313948B2/en active Active
- 2009-11-13 NZ NZ592413A patent/NZ592413A/xx unknown
- 2009-11-13 EP EP09752688.3A patent/EP2358675B9/en active Active
- 2009-11-13 TW TW098138707A patent/TWI443087B/zh active
- 2009-11-13 NZ NZ592543A patent/NZ592543A/xx unknown
- 2009-11-13 SI SI200930435T patent/SI2358675T1/sl unknown
- 2009-11-13 CN CN200980144708.1A patent/CN102209712B/zh active Active
- 2009-11-13 SI SI200930419T patent/SI2358676T1/sl unknown
- 2009-11-13 SG SG2011035169A patent/SG171311A1/en unknown
- 2009-11-13 WO PCT/US2009/064304 patent/WO2010056938A1/en active Application Filing
- 2009-11-13 WO PCT/US2009/064308 patent/WO2010056941A1/en active Application Filing
- 2009-11-13 JP JP2011536493A patent/JP5529150B2/ja active Active
- 2009-11-13 PT PT97526883T patent/PT2358675E/pt unknown
- 2009-11-13 EP EP09752687A patent/EP2358674B1/en active Active
- 2009-11-13 AU AU2009313951A patent/AU2009313951B2/en active Active
- 2009-11-13 MX MX2011005088A patent/MX2011005088A/es active IP Right Grant
- 2009-11-13 RU RU2011123890/04A patent/RU2503662C2/ru active
- 2009-11-13 BR BRPI0921595A patent/BRPI0921595B8/pt active IP Right Grant
- 2009-11-13 MX MX2011005089A patent/MX2011005089A/es active IP Right Grant
- 2009-11-13 CA CA2739992A patent/CA2739992C/en active Active
- 2009-11-13 CN CN200980145228.7A patent/CN102216272B/zh active Active
- 2009-11-13 BR BRPI0921596-4A patent/BRPI0921596B1/pt active IP Right Grant
- 2009-11-13 AR ARP090104419A patent/AR074128A1/es active IP Right Grant
- 2009-11-13 US US12/617,838 patent/US8304433B2/en active Active
- 2009-11-13 WO PCT/US2009/064306 patent/WO2010056939A1/en active Application Filing
- 2009-11-13 PL PL09752988T patent/PL2358676T3/pl unknown
- 2009-11-13 US US12/617,845 patent/US8247433B2/en active Active
- 2009-11-13 CN CN2009801452272A patent/CN102216271B/zh active Active
- 2009-11-13 SI SI200930543T patent/SI2358674T1/sl unknown
- 2009-11-13 DK DK09752687.5T patent/DK2358674T3/da active
- 2009-11-13 MY MYPI20111925 patent/MY151211A/en unknown
- 2009-11-13 DK DK09752988.7T patent/DK2358676T3/da active
- 2009-11-13 ES ES09752688T patent/ES2396583T3/es active Active
- 2009-11-13 EP EP09752988A patent/EP2358676B1/en active Active
- 2009-11-13 CA CA2742105A patent/CA2742105C/en active Active
- 2009-11-13 CA CA2742114A patent/CA2742114C/en active Active
- 2009-11-13 TW TW098138705A patent/TWI441810B/zh active
- 2009-11-13 RU RU2011123875/04A patent/RU2515612C2/ru active
- 2009-11-13 PT PT97526875T patent/PT2358674E/pt unknown
- 2009-11-13 PT PT97529887T patent/PT2358676E/pt unknown
- 2009-11-13 MX MX2011005090A patent/MX2011005090A/es active IP Right Grant
- 2009-11-13 KR KR1020117013512A patent/KR101656338B1/ko active IP Right Grant
- 2009-11-13 PL PL09752687T patent/PL2358674T3/pl unknown
- 2009-11-13 AR ARP090104418A patent/AR074350A1/es not_active Application Discontinuation
- 2009-11-13 ES ES09752687T patent/ES2401224T3/es active Active
- 2009-11-13 BR BRPI0921593A patent/BRPI0921593B8/pt active IP Right Grant
- 2009-11-13 TW TW098138704A patent/TWI461407B/zh active
- 2009-11-13 JP JP2011536491A patent/JP5506813B2/ja active Active
- 2009-11-13 AU AU2009313949A patent/AU2009313949B2/en not_active Ceased
- 2009-11-13 US US12/617,821 patent/US8304432B2/en active Active
- 2009-11-13 JP JP2011536490A patent/JP5598798B2/ja active Active
- 2009-11-13 PL PL09752688T patent/PL2358675T3/pl unknown
-
2011
- 2011-04-10 IL IL212230A patent/IL212230A/en active IP Right Grant
- 2011-04-26 IL IL212452A patent/IL212452A0/en active IP Right Grant
- 2011-05-09 CO CO11056556A patent/CO6361988A2/es active IP Right Grant
- 2011-05-12 ZA ZA2011/03495A patent/ZA201103495B/en unknown
- 2011-05-12 CL CL2011001088A patent/CL2011001088A1/es unknown
- 2011-05-13 CL CL2011001093A patent/CL2011001093A1/es unknown
- 2011-05-25 CO CO11064614A patent/CO6361993A2/es active IP Right Grant
-
2012
- 2012-01-26 HK HK12100743.6A patent/HK1160449A1/xx not_active IP Right Cessation
- 2012-01-26 HK HK12100742.7A patent/HK1160448A1/xx unknown
- 2012-01-27 HK HK12100779.3A patent/HK1160452A1/xx unknown
- 2012-07-10 US US13/545,513 patent/US8802857B2/en active Active
- 2012-09-28 US US13/631,192 patent/US8604058B2/en active Active
- 2012-10-01 US US13/632,588 patent/US8592596B2/en active Active
- 2012-11-07 HR HRP20120897AT patent/HRP20120897T1/hr unknown
- 2012-11-13 HR HRP20120920AT patent/HRP20120920T1/hr unknown
- 2012-11-29 CY CY20121101168T patent/CY1113622T1/el unknown
- 2012-12-07 CY CY20121101189T patent/CY1113623T1/el unknown
- 2012-12-27 SM SM201200063T patent/SMT201200063B/it unknown
- 2012-12-28 SM SM201200065T patent/SMT201200065B/xx unknown
-
2013
- 2013-03-26 SM SM201300033T patent/SMT201300033B/xx unknown
- 2013-03-26 CY CY20131100256T patent/CY1113855T1/el unknown
- 2013-04-02 HR HRP20130300AT patent/HRP20130300T1/hr unknown
- 2013-10-23 US US14/060,846 patent/US9073859B2/en active Active
- 2013-11-04 US US14/070,887 patent/US9162982B2/en active Active
-
2014
- 2014-02-25 JP JP2014033727A patent/JP2014098033A/ja not_active Withdrawn
- 2014-03-07 JP JP2014044653A patent/JP2014101384A/ja not_active Withdrawn
- 2014-03-12 JP JP2014048387A patent/JP2014139209A/ja not_active Withdrawn
- 2014-07-08 US US14/325,863 patent/US9187423B2/en active Active
-
2015
- 2015-06-02 US US14/728,079 patent/US20160022660A1/en not_active Abandoned
- 2015-09-09 US US14/848,933 patent/US9675599B2/en active Active
-
2017
- 2017-05-04 US US15/586,531 patent/US10226454B2/en active Active
- 2017-05-10 US US15/591,419 patent/US10034870B2/en active Active
-
2018
- 2018-06-13 US US16/007,233 patent/US10206913B2/en active Active
-
2019
- 2019-01-03 US US16/239,265 patent/US10441579B2/en active Active
- 2019-01-10 US US16/244,956 patent/US10576073B2/en active Active
- 2019-06-11 AR ARP190101607A patent/AR114965A2/es unknown
- 2019-09-04 US US16/559,928 patent/US10722504B2/en active Active
-
2020
- 2020-01-16 US US16/744,551 patent/US10946006B2/en active Active
- 2020-06-17 US US16/903,579 patent/US10946007B2/en active Active
-
2021
- 2021-02-03 US US17/248,692 patent/US11723900B2/en active Active
- 2021-02-05 US US17/248,737 patent/US11596624B2/en active Active
-
2023
- 2023-02-28 US US18/115,436 patent/US20230201181A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921593B8 (pt) | processo para preparar compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina e compostos relacionados | |
LTC2331547I2 (lt) | Pirolopirimidino junginiai, kaip CDK inhibitoriai | |
BR112012012584A2 (pt) | "processo para preparar sais de 4,5-diidroisoxazol-3-tiocarboxamidina 5,5-dissubstituídos de fórmula (i)" | |
BRPI0923576A2 (pt) | Manutenção de informação de grupo de assinante privado para controle de acesso | |
BR112012007828A2 (pt) | compostos, processo para preparar os compostos, e, composição farmacêutica. | |
BR112015004029A8 (pt) | processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo, e, composto | |
NO20083057L (no) | Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer | |
BR112012006031A2 (pt) | processo para preparação de compostos azabicíclicos. | |
BR112013000750A2 (pt) | 1-hidroxiimino-3-fenil-propanos | |
BR112013023924A2 (pt) | novos compostos substituídos com halogênio | |
BRPI0813499B8 (pt) | compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos | |
BR112013010018A2 (pt) | inibidores de cdk | |
BRPI1005940A2 (pt) | processo para preparar compostos de 2-nitrobifenila de fórmula i, compostos de 2-aminobifenila de fórmula vi, n-acil-2-aminobifenilas da fórmula geral (vii), composto de fórmula i, composto de fórmula ii, composto de fórmula iii e composto de fórmula x.1 ou x.2 | |
BRPI1016219B8 (pt) | composto indazol substituído com oxazol, e, composição farmacêutica | |
MA32877B1 (fr) | Composes organiques | |
BR112014010576A8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
EA201171065A1 (ru) | Очистка 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
BRPI1012638B8 (pt) | métodos e intermediários para preparar agentes farmacêuticos | |
BRPI0518203A2 (pt) | mÉtodos para preparaÇço de compostos indazol | |
BR112014010401A2 (pt) | inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina | |
PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
NO20090250L (no) | Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte | |
BRPI0922381A2 (pt) | "processo para síntese de di-ou oligossacarídeos de l-fucose e novos derivados intermediários de 2,3,4-tribenzil-fucose dos mesmos." | |
BR112013001111A2 (pt) | processo para a produção do composto da fórmula 1, processo para a produção de um composto da fórmula a, processo para a produção dos compostos da fórmula d, composto da fórmula e, composto da fórmula f e novos compostos | |
CL2016001172A1 (es) | Nuevos inhibidores de dgat2. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 211/22 Ipc: C07D 211/22 (2006.01), A61K 31/4409 (2006.01), A61 |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |